Despite the approval and successful market launch of tapinarof and benvitimod, little information is available on the pharmaceutical development of AHR agonists for therapeutic application in IBD or other chronic-inflammatory indications.322,454,455 Considering the immense scientific achievements and conclusions from many preclinical studies that AHR might represent a promising therapeutic target over the last two decades,446 this situation is rather amazing and needs some explanation. The gene discussed is AHR; the disease is inflammatory bowel disease.